Drugs / Pyroptosis-inducible Newcasstle Disease Oncolytic Virus
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06883149 | Mar 2025 → Jun 2026 overdue | cancer | Chinese PLA General Hospital | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pyroptosis-inducible Newcasstle Disease Oncolytic Virus | “Treatment of Pyroptosis-inducible Newcasstle Disease Oncolytic Virus (PIN) Plus Anti-PD1 in Late-stage Advanced Solid Tumors---An Open Label Single-arm Phase I Clinical Trial” NCT06883149 ↗ |
| Known as | PIN | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06883149 ↗ |
| Modality | Other / unclassified | “Pyroptosis-inducible Newcasstle Disease Oncolytic Virus (PIN)” NCT06883149 ↗ |
| Route | Other | “PIN injection frequency: day0 and day 3” NCT06883149 ↗ |